Skandinaviska Enskilda Banken (SEB)
ITCI

Skandinaviska Enskilda Banken (SEB)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,000
Closed -$4.62M – 909
2025
Q1 		$4.62M Sell
35,000
-243,711
-87% -$30.4M 0.02% 430
2024
Q4 		$23.3M Hold
278,711
– – 0.11% 161
2024
Q3 		$20.4M Buy
278,711
+19,590
+8% +$1.47M 0.09% 177
2024
Q2 		$17.7M Buy
259,121
+128,908
+99% +$8.94M 0.09% 190
2024
Q1 		$9M Sell
130,213
-160,718
-55% -$11M 0.04% 292
2023
Q4 		$20.8M Sell
290,931
-113,181
-28% -$6.51M 0.12% 166
2023
Q3 		$21M Hold
404,112
– – 0.14% 152
2023
Q2 		$25.6M Buy
404,112
+135,749
+51% +$8.46M 0.17% 123
2023
Q1 		$14.5M Sell
268,363
-104,713
-28% -$5.06M 0.1% 214
2022
Q4 		$19.8M Sell
373,076
-10,489
-3% -$526K 0.15% 156
2022
Q3 		$17.8M Hold
383,565
– – 0.14% 146
2022
Q2 		$21.9M Sell
383,565
-8,372
-2% -$475K 0.16% 129
2022
Q1 		$24M Sell
391,937
-4,342
-1% -$225K 0.14% 140
2021
Q4 		$20.7M Buy
396,279
+103,816
+35% +$4.36M 0.11% 176
2021
Q3 		$10.9M Hold
292,463
– – 0.06% 272
2021
Q2 		$11.9M Buy
292,463
+266,741
+1,037% +$9.86M 0.07% 254
2021
Q1 		$874K Buy
+25,722
New +$892K 0.01% 860

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ITCI Position: Q2 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 35,000 shares — an estimated $4.62M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ITCI in Q1 2021 and held it in 17 quarters. The position peaked at $25.6M in Q2 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 35,000 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $4.62M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Intra-Cellular Therapies Inc. in Q1 2021 and held it in 17 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Intra-Cellular Therapies Inc. position peaked at $25.6M in Q2 2023.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2025, filed 13 Aug 2025.